Neelima Denduluri, MD on CDK 4/6 Drug Target Activation Mapping @ndenduluri1 @VCSpecialists

Neelima Denduluri, MD @ndenduluri1 of Virginia Cancer Specialists @VCSpecialists discusses CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13029